Pembrolizumab Monotherapy for NSCLC Extends Survival

Abstract The PD-1 inhibitor pembrolizumab may be a better first-line treatment than chemotherapy for many patients with advanced non–small cell lung cancer: In a phase III trial, patients with PD-L1 expression of 1% or higher treated with the drug had better overall survival, a longer duration of response, and fewer side effects than patients who received chemotherapy alone.